U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14O4S
Molecular Weight 314.356
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROFECOXIB

SMILES

CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3

InChI

InChIKey=RZJQGNCSTQAWON-UHFFFAOYSA-N
InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

HIDE SMILES / InChI

Molecular Formula C17H14O4S
Molecular Weight 314.356
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Rofecoxib is a nonsteroidal anti-inflammatory drug which selectively inhibits COX-2 and subsequent prostaglandin synthesis. The drug was developed by Merk and approved by FDA in 1999 for relief of signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles under the name Vioxx. Later on Merck voluntarily withdrawn Vioxx from the market due to safety concerns (high risk of heart attack and stroke).

CNS Activity

Curator's Comment: Rofecoxib has been shown to cross the blood-brain barrier in rats.

Originator

Curator's Comment: # Merck

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.02 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

1999
Palliative
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

1999
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

1999
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

1999
Primary
VIOXX

Approved Use

For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
321 ng/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4018 ng × h/mL
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17 h
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ROFECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12.5 mg 1 times / day steady, oral
Recommended
Dose: 12.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 12.5 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 6
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 6
Sources:
Disc. AE: Renal impairment...
AEs leading to
discontinuation/dose reduction:
Renal impairment (grade 1, 1 patient)
Sources:
50 mg 1 times / day steady, oral
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 33
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 33
Sources:
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Disc. AE: Cardiac thrombosis...
Other AEs: Cardiac thrombosis...
AEs leading to
discontinuation/dose reduction:
Cardiac thrombosis (grade 5, 4 patients)
Other AEs:
Cardiac thrombosis (16 patients)
Sources:
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Disc. AE: Dyspepsia, Nausea...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (4.4%)
Nausea (2.4%)
Dizziness (2.1%)
Sources:
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Disc. AE: Death...
Other AEs: Hemorrhage, Edema...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1653 patients)
Other AEs:
Hemorrhage (3915 patients)
Edema (3677 patients)
Thrombosis (1917 patients)
Embolism (233 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Renal impairment grade 1, 1 patient
Disc. AE
12.5 mg 1 times / day steady, oral
Recommended
Dose: 12.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 12.5 mg, 1 times / day
Co-administed with::
Gefitinib(250 mg)
Sources:
unhealthy, 44-76 years
n = 6
Health Status: unhealthy
Condition: non small-cell lung cancer
Age Group: 44-76 years
Sex: M+F
Population Size: 6
Sources:
Cardiac thrombosis 16 patients
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Cardiac thrombosis grade 5, 4 patients
Disc. AE
25 mg 1 times / day steady, oral
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 58–71years
n = 1167
Health Status: unhealthy
Condition: colorectal cancer
Age Group: 58–71years
Sex: M+F
Population Size: 1167
Sources:
Dizziness 2.1%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Nausea 2.4%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Dyspepsia 4.4%
Disc. AE
25 mg 1 times / day multiple, oral (max)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 66.8 years
n = 2896
Health Status: unhealthy
Condition: painful osteoarthritis of the knee or hip
Age Group: 66.8 years
Sex: M+F
Population Size: 2896
Sources:
Thrombosis 1917 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Embolism 233 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Edema 3677 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Hemorrhage 3915 patients
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Death grade 5, 1653 patients
Disc. AE
25 mg 1 times / day multiple, oral (typical)
Recommended
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, adult
n = 2200000
Health Status: unhealthy
Condition: various
Age Group: adult
Sex: M+F
Population Size: 2200000
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
weak (co-administration study)
Comment: A 30% interactions, additional studies would be necessary reduction of the AUC of the CYP3A4 substrate to more completely elucidate the drug interaction midazolam was observed with rofecoxib 25mg profile of rofecoxib and determine the clinical rele- daily. This reduction is most probably due to in- vance of any possible interactions. creased first-pass metabolism through induction of intestinal CYP3A4 by rofecoxib
Page: 4.0
no
no
no
no
yes [IC50 1.17 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.
2001
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
2001
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
2001
Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.
2001
Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.
2001
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
2001 Apr
[The coxibs, third generation anti-inflammatories].
2001 Apr
Gastrointestinal damage induced by celecoxib and rofecoxib in rats.
2001 Apr
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
2001 Apr
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.
2001 Aug
The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus.
2001 Feb
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
2001 Feb
FDA refuses companies' request to drop ulcer warning.
2001 Feb 17
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
2001 Feb 19
Efficacy of cyclooxygenase-2-specific inhibitors.
2001 Feb 19
Anti-inflammatory drugs, cyclooxygenases and other factors.
2001 Jan
Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain.
2001 Jan
[Stomach-saving "Coxibs". No reason for therapeutic risks].
2001 Jan 18
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
2001 Jul
Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.
2001 Jul
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
2001 Jul
Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.
2001 Jul
Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde.
2001 Jul
Ibuprofen to rofecoxib: what does it all mean and what do I do now?
2001 Jul-Aug
Gastric preconditioning induced by short ischemia: the role of prostaglandins, nitric oxide and adenosine.
2001 Jul-Aug
Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure.
2001 Jun
Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
2001 Jun
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
2001 Jun 1
Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.
2001 Jun 16
[Safety of specific cyclo-oxygenase 2 inhibitors].
2001 Jun 2
Cyclooxygenase-2 inhibition and renal function.
2001 Jun 5
[Therapy of arthrosis. Life threatening gastrointestinal events can be reduced].
2001 Jun 7
Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial.
2001 Mar
Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
2001 Mar
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
2001 Mar
[Cyclooxygenase inhibitors].
2001 Mar 17
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
2001 May
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
2001 May
Osteoarthritis. A primary care approach for physicians in 2000 and beyond.
2001 May
Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis.
2001 May
EULAR recommendations for the management of knee osteoarthritis.
2001 May
[Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable].
2001 May 3
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
COX-1 and COX-2 inhibitors.
2001 Oct
Tolerability of rofecoxib.
2001 Sep
Nephrotoxicity of selective COX-2 inhibitors.
2001 Sep
Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves.
2001 Sep 21
Pain relief at a price. A blow to the heart?
2001 Sep 3
Patents

Sample Use Guides

Osteoarthritis: the recommended starting dose of rofecoxib (VIOXX) is 12.5 mg once daily. Rheumatoid Arthritis: the recommended dose is 50 mg once daily. Management of Acute Pain and Treatment of Primary Dysmenorrhea: the recommended dose is 50 mg once daily. Acute Treatment of Migraine Attacks with or without aura: the recommended dose is 25 mg once daily.
Route of Administration: Oral
THP-1 human macrophages and peripheral blood mononuclear cells were incubated with rofecoxib (at 5, 10, 25 uM). The presence of rofecoxib (at high concentrations) significantly decreased expression of 27-hydroxylase and ABCA1, interfering with normal cholesterol outflow from macrophages.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:31:46 GMT 2023
Edited
by admin
on Sat Dec 16 16:31:46 GMT 2023
Record UNII
0QTW8Z7MCR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROFECOXIB
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-758705
Code English
rofecoxib [INN]
Common Name English
MK-966
Code English
TRM-201
Code English
VIOXX
Brand Name English
M01AH02
Code English
ROFECOXIB [MI]
Common Name English
NSC-720256
Code English
ROFECOXIB [MART.]
Common Name English
ROFECOXIB [USAN]
Common Name English
MK-0966
Code English
MK0966
Code English
TRM201
Code English
ROFECOXIB [VANDF]
Common Name English
Rofecoxib [WHO-DD]
Common Name English
4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
Systematic Name English
ROFECOXIB [ORANGE BOOK]
Common Name English
ROFECOXIB [JAN]
Common Name English
4-(P-(METHYLSULFONYL)PHENYL)-3-PHENYL-2(5H)-FURANONE
Common Name English
ROFECOXIB [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QM01AH02
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
NCI_THESAURUS C80509
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
FDA ORPHAN DRUG 181703
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
LIVERTOX NBK548628
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
WHO-ATC M01AH02
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
FDA ORPHAN DRUG 601917
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
Code System Code Type Description
DRUG BANK
DB00533
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
EVMPD
SUB04261MIG
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
NCI_THESAURUS
C1832
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
NSC
720256
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023567
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
IUPHAR
2893
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
CHEBI
8887
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
WIKIPEDIA
ROFECOXIB
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
USAN
JJ-32
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
MERCK INDEX
m9647
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY Merck Index
SMS_ID
100000091590
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
FDA UNII
0QTW8Z7MCR
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
PUBCHEM
5090
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
CAS
162011-90-7
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL122
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
HSDB
7262
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
DRUG CENTRAL
2397
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
INN
7768
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
NSC
758705
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
MESH
C116926
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY
RXCUI
232158
Created by admin on Sat Dec 16 16:31:47 GMT 2023 , Edited by admin on Sat Dec 16 16:31:47 GMT 2023
PRIMARY RxNorm
Related Record Type Details
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC